Abstract
Background Interferon-gamma release assay (IGRA) has emerged as a useful tool in identifying latent tuberculosis infection (LTBI). This assay can be performed through testing platforms, such as QuantiFERON-TB Gold Plus (QFT®-Plus). This in vitro test has been incorporated by several guidelines worldwide and has recently been considered for the diagnosis of LTBI by the World Health Organization (WHO). The possibility of systematically implementing IGRAs such as QFT®-Plus in centers that perform LTBI screening has been accelerated by the decreased availability of tuberculin skin testing (TST) in several countries. Nevertheless, the process to implement IGRA testing in routine clinical care has many gaps.
Methods The study utilized the expertise acquired by the laboratory teams of the Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil consortium during study protocol implementation of LTBI screening of TB close contacts.
Results RePORT-Brazil includes clinical research sites from Brazilian cities and is the largest multicenter cohort of TB close contacts to date in the country. Operational and logistical challenges faced during IGRA implementation in all four study laboratories are described, as well as the solutions that were developed and led to the successful establishment of IGRA testing in RePORT-Brazil.
Conclusions The problems identified and resolved in this study can assist laboratories implementing IGRAs, in addition to manufacturers of IGRAs providing effective technical support. This will facilitate the implementation of IGRA testing in countries with a high TB burden, such as Brazil.
Importance The interferon-gamma release assay (IGRA) has emerged as a useful tool in identifying persons with latent tuberculosis infection (LTBI). Although the implementation of IGRAs is of utmost importance, to our knowledge, there is scarce information on identification of logistical and technical challenges of systematic screening of for LTBI on a large scale. Thus, the problems identified and resolved in this study can assist laboratories implementing IGRAs, in addition to manufacturers of IGRAs providing effective technical support. This will facilitate the implementation of IGRA testing in countries with a high TB burden, such as Brazil.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by the Intramural Research Program of the Fundacao Oswaldo Cruz (B.B.A.), Intramural Research Program of the Fundacao Jose Silveira (B.B.A., M.S.R., B.M.F.N.), Departamento de Ciencia e Tecnologia (DECIT), Secretaria de Ciencia e Tecnologia (SCTIE), Ministerio da Saude (MS), Brazil [25029.000507/2013-07 to V.C.R.] and the National Institutes of Allergy and Infectious Diseases [U01-AI069923 to TRS, ABS, GA, BMFN, ATLQ, MCF, MSR, AB, ASRM, JGO, VCR, BD, JRLS,ALK, SC, TRS, BBA, and MCS]. MAP received a fellowship from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Finance code: 001). B.B.A, V.C.R. and A.K. are senior investigators whereas A.B.S. is a PhD fellow from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the principles of the Declaration of Helsinki. The RePORT-Brazil protocol was approved by the institutional review boards at each study site and at Vanderbilt University Medical Center. In additional, the present study was submitted to and approved by the Ethical Committee at Instituto de Pesquisa Clinica Evandro Chagas, Fundacao Oswaldo Cruz (FIOCRUZ), under the protocol registration number #688.067, Secretaria Municipal de Saude do Rio de Janeiro (SMS/RJ), under the protocol registration number #740.554, Hospital Universitario Clementino Fraga Filho, under the protocol registration number #852.519, Maternidade Climerio de Oliveira (MCO), Universidade Federal do Bahia (UFBA), under the protocol registration number #723.168 and Fundacao de Medicina Tropical Dr. Heitor Vieira Dourado (FMT-HVD), under the protocol registration number #807.595. The patients, parents or legal guardians read and signed the informed consent form prior to inclusion of the patients in the study. The study fulfills the principles of the Helsinki declaration and the 466/2012 resolution of the Brazilian National Health Council for research involving human participants.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.
